Shared on 06 Dec 25

Fair value Decreased 0.15%

GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead

Analysts have nudged their blended price target for Gilead Sciences slightly lower by about $0.20 to the low-$130s, reflecting modestly higher discount rates and more conservative HIV and oncology growth and margin assumptions, even as they highlight extended Biktarvy exclusivity, encouraging Yeztugo uptake, and anito cel driven oncology optionality as key long term value drivers. Analyst Commentary Bullish analysts largely frame the recent price target tweaks as fine tuning within an increasingly constructive long term view, pointing to extended HIV cash flows, a strengthening PrEP opportunity, and optionality in oncology despite early stage competitive readouts.

Shared on 22 Nov 25

Fair value Increased 1.02%

GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures

Analysts have modestly raised their price target for Gilead Sciences to $130.83 per share from $129.51. They cite the extended exclusivity period for Biktarvy and improved growth prospects in the HIV market as key drivers for the upward revision.

Shared on 08 Nov 25

Fair value Increased 1.79%

GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead

Gilead Sciences' price target has been raised by analysts from $127 to $145. This reflects confidence in stable HIV business trends and improved execution, which offsets ongoing oncology and cell therapy challenges.

Shared on 25 Oct 25

Fair value Increased 0.73%

Gilead Sciences' analyst price target has increased from $126 to $127 per share. Analysts point to continued strong uptake of the Yeztugo launch in HIV and the recent Biktarvy patent extension as supporting factors, despite some pipeline setbacks.

Shared on 10 Oct 25

Fair value Increased 1.12%

Gilead Sciences saw its analyst price target increase from $124.91 to $126.31. Analysts cited improved sales forecasts for key HIV treatments and enhanced revenue growth expectations as the primary drivers of the upward revision.

Shared on 04 Sep 25

Fair value Increased 0.43%

Analysts remain constructive on Gilead Sciences, citing strong HIV franchise performance, positive FDA developments, and favorable regulatory tailwinds offsetting minor pipeline setbacks, resulting in an unchanged consensus price target of $124.37. Analyst Commentary Yeztugo’s FDA approval and clean label, strong clinical data, and convenient twice-yearly dosing are seen as key drivers for Gilead’s HIV franchise growth, with analysts generally positive on long-term adoption despite initial ramp expectations being slow and some cannibalization of Descovy anticipated.

Shared on 07 May 25

Fair value Increased 8.70%

Shared on 30 Apr 25

Fair value Increased 0.37%

AnalystConsensusTarget has increased revenue growth from 2.8% to 3.2%.

Shared on 23 Apr 25

Fair value Increased 1.19%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on 16 Apr 25

Fair value Increased 0.90%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 0.036%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 0.46%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 10 Mar 25

Fair value Decreased 5.61%

AnalystConsensusTarget has increased revenue growth from 2.2% to 2.6% and increased profit margin from 26.6% to 29.6%.

Patent Extension And Policy Decisions Will Drive Access To Advanced Therapies

GILD: Extended HIV Franchise Will Offset Oncology And Policy Uncertainty Ahead

GILD: Extended Exclusivity And PrEP Opportunities Will Balance Ongoing Oncology And Policy Pressures

GILD: HIV Business Strength And Patent Extension Will Balance Oncology Risks Ahead

Shared on 25 Oct 25

Shared on 10 Oct 25

Shared on 04 Sep 25

Shared on 07 May 25

Shared on 30 Apr 25

Shared on 23 Apr 25

Shared on 16 Apr 25

Shared on 09 Apr 25

Shared on 02 Apr 25

Shared on 26 Mar 25

Shared on 19 Mar 25

Shared on 10 Mar 25